Top

Published in:

01-06-2007 | CLINICAL TRAIL

A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up

Authors: Janice M. Walshe, Arlene W. Berman, Ujala Vatas, Seth M. Steinberg, William F. Anderson, Marc E. Lippman, Sandra M. Swain

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Abstract

Purpose To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy.

Patients and methods Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy.

Results Median patient age was 61 years (38–74 years). Twenty-one patients (68%) had 1–3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9–78.9%), at 15 years is 51.6% (95% CI: 34.8–68%), and at 20 years is 42.4% (95% CI: 25.8–60.8%).

Conclusion To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.

Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMed

Giordano SH, Cohen DS, Buzdar AU et al (2004) Breast carcinoma in men: a population-based study. Cancer 101(1):51–57PubMedCrossRef

Anderson WF, Devesa SS (2005) In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer 104(8):1733–1741PubMedCrossRef

Wainwright J (1927) Carcinoma of the male breast. Arch Surg 14:836–859

Heller KS, Rosen PP, Schottenfeld D et al (1978) Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 188(1):60–65PubMedCrossRef

Ramantanis G, Besbeas S, Garas JG (1980) Breast cancer in the male: a report of 138 cases. World J Surg 4(5):621–623PubMedCrossRef

Stierer M, Rosen H, Weitensfelder W et al (1995) Male breast cancer: Austrian experience. World J Surg 19(5):687–692; discussion 692–683PubMedCrossRef

Donegan WL, Redlich PN, Lang PJ et al (1998) Carcinoma of the breast in males: a multiinstitutional survey. Cancer 83(3):498–509PubMedCrossRef

Erlichman C, Murphy KC, Elhakim T (1984) Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 2(8):903–909PubMed

10.

Yap HY, Tashima CK, Blumenschein GR et al (1979) Male breast cancer: a natural history study. Cancer 44(2):748–754PubMedCrossRef

11.

Salvadori B, Saccozzi R, Manzari A et al (1994) Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 30A(7):930–935PubMedCrossRef

12.

Cutuli B, Lacroze M, Dilhuydy JM et al (1995) Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A(12):1960–1964PubMedCrossRef

13.

Guinee VF, Olsson H, Moller T et al (1993) The prognosis of breast cancer in males. A report of 335 cases. Cancer 71(1):154–161PubMedCrossRef

14.

Goss PE, Reid C, Pintilie M et al (1999) Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85(3):629–639PubMedCrossRef

15.

Spence RA, MacKenzie G, Anderson JR et al (1985) Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases. Cancer 55(3):648–652PubMedCrossRef

16.

Yildirim E, Berberoglu U (1998) Male breast cancer: a 22-year experience. Eur J Surg Oncol 24(6):548–552PubMedCrossRef

17.

Ribeiro GG (1977) Carcinoma of the male breast: a review of 200 cases. Br J Surg 64(6):381–383PubMedCrossRef

18.

Ribeiro G (1985) Male breast carcinoma—a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 51(1):115–119PubMed

19.

Crichlow RW (1974) Breast cancer in men. Semin Oncol 1(2):145–152PubMed

20.

Ribeiro G, Swindell R, Harris M et al (1996) A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 5:141–146CrossRef

21.

Robison R, Montague ED (1982) Treatment results in males with breast cancer. Cancer 49(2):403–406PubMedCrossRef

22.

Appelqvist P, Salmo M (1982) Prognosis in carcinoma of the male breast. Acta Chir Scand 148(6):499–502PubMed

23.

Crichlow RW (1972) Carcinoma of the male breast. Surg Gynecol Obstet 134(6):1011–1019PubMed

24.

Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294(8):405–410PubMedCrossRef

25.

Bagley CS, Wesley MN, Young RC et al (1987) Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 10(1):55–60PubMedCrossRef

26.

Beahrs OH, Myers M (eds) (1983) Manual for staging of cancer-american joint committee on cancer. J.B. Lippincott Co., Philadelphia

27.

Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observation. J Am Statist Assoc 53:457–481CrossRef

28.

Surveillance, Epidemiology, End results (SEER) Program (www.seer.cancer.gov) SEER STAT database: Incidence- SEER 17 Regs Public-use; November 2005 submission for survival analyses [1973–2003 varying], National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006

29.

Patel HZ II, Buzdar AU, Hortobagyi GN (1989) Role of adjuvant chemotherapy in male breast cancer. Cancer 64(8):1583–1585PubMedCrossRef

30.

Izquierdo MA, Alonso C, De Andres L et al (1994) Male breast cancer. Report of a series of 50 cases. Acta Oncol 33(7):767–771PubMed

31.

Giordano SH, Perkins GH, Broglio K et al (2005) Adjuvant systemic therapy for male breast carcinoma. Cancer 104(11):2359–2364PubMedCrossRef

32.

Rosenblatt KA, Thomas DB, McTiernan A et al (1991) Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 83(12):849–854PubMedCrossRef

33.

D’Avanzo B, La Vecchia C (1995) Risk factors for male breast cancer. Br J Cancer 71(6):1359–1362PubMed

34.

Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993) Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53(4):538–549PubMedCrossRef

35.

Schottenfeld D, Lilienfeld AM, Diamond H (1963) Some observations on the epidemiology of breast cancer among males. Am J Public Health 53:890–897PubMedCrossRef

36.

Storm HH, Olsen J (1999) Risk of breast cancer in offspring of male breast-cancer patients. Lancet 353(9148):209PubMedCrossRef

37.

Hemminki K, Vaittinen P (1999) Male breast cancer: risk to daughters. Lancet 353(9159):1186–1187PubMedCrossRef

38.

Travis LB, Hill DA, Dores GM et al (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290(4):465–475PubMedCrossRef

39.

Auvinen A, Curtis RE, Ron E (2002) Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 94(17):1330–1332PubMed

40.

Struewing JP, Brody LC, Erdos MR et al (1995) Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57(1):1–7PubMed

41.

Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676–689

42.

Osorio A, Barroso A, Martinez B et al (2000) Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82(7):1266–1270PubMedCrossRef

43.

Sasano H, Kimura M, Shizawa S et al (1996) Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab 81(8):3063–3067PubMedCrossRef

44.

Anderson WF, Althuis MD, Brinton LA et al (2004) Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83(1):77–86PubMedCrossRef

45.

Ribeiro G, Swindell R (1992) Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65(2):252–254PubMed

46.

Nahleh ZA (2006) Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 32(2):101–105PubMedCrossRef

47.

Munoz de Toro MM, Maffini MV, Kass L et al (1998) Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 67(4):333–339CrossRef

48.

Weber-Chappuis K, Bieri-Burger S, Hurlimann J (1996) Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32A(10):1686–1692PubMedCrossRef

49.

http://www.swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=1995

Title: A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up
Authors: Janice M. Walshe
Arlene W. Berman
Ujala Vatas
Seth M. Steinberg
William F. Anderson
Marc E. Lippman
Sandra M. Swain
Publication date: 01-06-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-006-9363-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case–control study

A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7

Evaluating the organization and delivery of breast cancer services: use of performance measures to identify knowledge gaps

Establishment, growth and in vivo differentiation of a new clonal human cell line, EM-G3, derived from breast cancer progenitors

DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population

Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff

Keynote webinar | Spotlight on antibody–drug conjugates in cancer